The Medical Device industry is entering a period of substantial change.
The primary drivers include increased pricing pressures, reimbursement challenges, and regulation coupled with rapid growth in emerging markets and general aging of the global population. Companies are consolidating as mergers and acquisitions are at an all-time high. While pricing flexibility remains for the most innovative technologies, companies are being pressured to demonstrate much greater economic value. The industry is being asked to improve clinical outcomes, expand access AND optimize cost and efficiency.
Accel provides deep expertise and a unique point of view in developing and implementing leading-edge product development and operations strategies. Our services support the rapid and effective development of new therapies to address unmet clinical needs and provide greater access in global markets. Our global manufacturing strategies consider product cost, tax, core competencies and business continuity (e.g., with an emphasis on reducing labor and overhead costs, optimizing effective tax rates, and expanding the presence in BRIC countries). Since our founding in 1998, Accel consultants have actively supported MedTech industry leaders (including eight of the top 10) to achieve significant and lasting results.
A substantial portion of Biotechnology is becoming the risk diversifier of the Pharmaceutical Industry.
More and more, Biotechnology is sought out as a solution where previously only pharmaceutical compounds were envisioned. This dynamic presents a business opportunity as large Pharmaceutical companies look for partners and acquisitions but also places a high premium on sophisticated management of Biotechnology’s new product developments. Biotechnology development is not a staggered workflow of research followed by manufacturing development; it is a unified and coordinated effort that requires standard platform development to enable reliably repeatable manufacturing delivery. It is the simultaneous development of the manufacturing process and the biologic.
With our focus on improving competitive profitability, Accel applies expertise in complex development and operations to restructure, streamline, and recreate practical biotechnology development. From the perspective of the working levels, we pare out unnecessary management loops and second-guessing; simultaneously for executive leadership, we implement the right controls in development efforts to highlight pertinent business metrics without the noise. The end results of engaging Accel include recovered development efforts, highly reliable project schedules and targets, and team-level and management-level organizational mechanisms developed and implemented for long lasting improvements in corporate culture.
Major pharmaceutical companies spend $2-$10 billion to research, develop, trial, approve, and launch a typical new drug.
Large, highly distributed, and multi-functional organizations are notoriously inefficient at managing and driving complex efforts, and the end result in the pharmaceutical industry is poor R&D productivity, unpredictable schedule achievement, and low-yield product portfolios. Reimbursement cost pressures also add to the profitability challenge and highlight the need for far better efficiency. An increasingly sophisticated patient market raises the bar even further on strategic selections, patient outcomes, and marketing effectiveness.
Accel provides proven expertise in evaluating R&D productivity and redeploying effective processes, team behaviors, and overall project successes. With our focus on competitive profitability, we can assist in paring down development pipelines, assisting the decision-making with objective industry research and metric-based measures of development portfolios. We can facilitate your core group of decision makers, enabling each to bring a valuable perspective to the table, and unifying them to common ground instead of allowing an obstacle-based culture to take over. Accel also applies the same principles at the tactical level, leading/facilitating cross-functional development teams to achieve each critical milestone, changing the culture to practice a needle-focus on schedule achievement while accomplishing all development, clinical, and operational goals.